Presentation by Teymur Noori, ECDC, at AIDS 2018 conference during teh joint ECDC and EACS satellite "Getting to 90: Addressing inequalities in the HIV continuum of care in Europe and Central Asia"
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation by: Jens Lundgren, CHIP
In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation by: Masoud Dara, WHO Regional Office for Europe
In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation by: Julia del Amo, Instituto de Salud Carlos III, Madrid
In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation by: Amanda Mocroft, UCL
In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation by: Valerie Delpech, Public Health Engand
In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation by: Jens Lundgren, CHIP
In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation by: Masoud Dara, WHO Regional Office for Europe
In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation by: Julia del Amo, Instituto de Salud Carlos III, Madrid
In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation by: Amanda Mocroft, UCL
In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation by: Valerie Delpech, Public Health Engand
In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
Antibiotic resistance is one of the biggest threats facing us today.
Why it is relevant to you: without effective antibiotics many routine treatments will become increasingly dangerous. Setting broken bones, basic operations, even chemotherapy and animal health all rely on access to antibiotics that work.
What we want you to do: To slow resistance we need to cut the unnecessary use of antibiotics. We invite the public, students and educators, farmers, the veterinary and medical communities and professional organisations, to become Antibiotic Guardians.
Call to action: Choose one simple pledge about how you’ll make better use of antibiotics and help save these vital medicines from becoming obsolete.
Presentation by Daniel Simões, HIV in Europe, Portugal , at AIDS 2018 conference during the joint ECDC and EACS satellite "Getting to 90: Addressing inequalities in the HIV continuum of care in Europe and Central Asia"
Presentation by Jens Lundgren, Rigshospitalet, University of Copenhagen - European AIDS Clinical Society, Denmark, at AIDS 2018 conference during the joint ECDC and EACS satellite "Getting to 90: Addressing inequalities in the HIV continuum of care in Europe and Central Asia"
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation by: Mika Salminen, European HA-REACT project
In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation by: Sini Pasanen, Civil Society Forum/AIDS Action Europe
In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
AIDS and its vengeance saw a back seat after we achieved the zero level of growth for it. But worries regarding the people living with AIDS are still on and we need to take care of these segments in an integrated manner
Provides information on management of syphilis in patients with HIV, including clinical recommendations and key points regarding transmission, prevention, screening, treatment, follow-up, and partner exposure.
Find more information at https://www.hivguidelines.org/sti-care/syphilis/
Sponsored by the New York State Department of Health (NYSDOH) AIDS Institute (AI) and the HIV Clinical Guidelines Program
Gabriel Wagner, MD
Assistant Professor of Medicine
Division of Infectious Diseases & Global Public Health
Department of Medicine
University of California, San Diego
Dr. Kathleen Brady (AACO)'s annual epidemiological update. This presentation was given to the Philadelphia EMA Ryan White Planning Council on Thursday, February 20, 2014.
What is the current situation of HIV in Europe and Central Asia?
How can we more effectively prevent new infections?
Presentation by Anastasia Pharris,
European Centre for Disease Prevention and Control (ECDC)
at Glasgow HIV Drug Therapy Conference
28 October 2018
Antibiotic resistance is one of the biggest threats facing us today.
Why it is relevant to you: without effective antibiotics many routine treatments will become increasingly dangerous. Setting broken bones, basic operations, even chemotherapy and animal health all rely on access to antibiotics that work.
What we want you to do: To slow resistance we need to cut the unnecessary use of antibiotics. We invite the public, students and educators, farmers, the veterinary and medical communities and professional organisations, to become Antibiotic Guardians.
Call to action: Choose one simple pledge about how you’ll make better use of antibiotics and help save these vital medicines from becoming obsolete.
Presentation by Daniel Simões, HIV in Europe, Portugal , at AIDS 2018 conference during the joint ECDC and EACS satellite "Getting to 90: Addressing inequalities in the HIV continuum of care in Europe and Central Asia"
Presentation by Jens Lundgren, Rigshospitalet, University of Copenhagen - European AIDS Clinical Society, Denmark, at AIDS 2018 conference during the joint ECDC and EACS satellite "Getting to 90: Addressing inequalities in the HIV continuum of care in Europe and Central Asia"
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation by: Mika Salminen, European HA-REACT project
In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation by: Sini Pasanen, Civil Society Forum/AIDS Action Europe
In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
AIDS and its vengeance saw a back seat after we achieved the zero level of growth for it. But worries regarding the people living with AIDS are still on and we need to take care of these segments in an integrated manner
Provides information on management of syphilis in patients with HIV, including clinical recommendations and key points regarding transmission, prevention, screening, treatment, follow-up, and partner exposure.
Find more information at https://www.hivguidelines.org/sti-care/syphilis/
Sponsored by the New York State Department of Health (NYSDOH) AIDS Institute (AI) and the HIV Clinical Guidelines Program
Gabriel Wagner, MD
Assistant Professor of Medicine
Division of Infectious Diseases & Global Public Health
Department of Medicine
University of California, San Diego
Dr. Kathleen Brady (AACO)'s annual epidemiological update. This presentation was given to the Philadelphia EMA Ryan White Planning Council on Thursday, February 20, 2014.
What is the current situation of HIV in Europe and Central Asia?
How can we more effectively prevent new infections?
Presentation by Anastasia Pharris,
European Centre for Disease Prevention and Control (ECDC)
at Glasgow HIV Drug Therapy Conference
28 October 2018
Presentation from the opening session of the 17th European AIDS Conference (EACS) 2019, Basel, Switzerland.
Presenter: Anastasia Pharris, European Centre for Disease Prevention and Control.
Presentation at European Harm Reduction Conference
Bucharest, 21 November 2018
Author Anastasia Pharris, European Centre for Disease Prevention and Control (ECDC)
Presentation by ECDC HIV expert Anastasia Pharris on epidemiological challenges for the HIV response in Europe.
Presented at: 16th European AIDS Conference, 26 October 2017, Milan.
Presentation by Chloe Orkin, Royal London Hospital - BHIVA, United Kingdom, at AIDS 2018 conference during the joint ECDC and EACS satellite "Getting to 90: Addressing inequalities in the HIV continuum of care in Europe and Central Asia"
Сравнение режимов лечения ВИЧ в разрезе различных клинических сценариев.ART...hivlifeinfo
This downloadable slideset summarizes optimal evidence-based antiretroviral therapy management strategies for a series of challenging clinical cases and is based on a satellite symposium presented at HIV Glasgow 2016.
Format: Microsoft PowerPoint (.ppt)
File size: 1.32 MB
Date posted: 11/11/2016
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation by: Teymur Noori, ECDC
In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
Kathleen Brady from the Philadelphia Department of Public Health presented her annual updated on the HIV Epidemic in Philadelphia at a February 2015 combined meeting of the Philadelphia Ryan White Part A Planning Council and the HIV Prevention Planning Group.
Presentation during the 17th European AIDS Conference (EACS) 2019 looking at the status of HIV pre-exposure prophylaxis PrEP in Europe..
Presenter: Teymur Noori, European Centre for Disease Prevention and Control (ECDC)
Summary slides on the epidemiological situation in the EU/EEA.
2018 surveillance data.
Report and ppt slides available from: http://bit.ly/HIVAIDSsurv18
ECDC symposium "Responding to two of the main STI threats of our time: syphilis and antimicrobial resistant Neisseria gonorrhoeae"
Presentation by: Otilia Mårdh
Presented at: IUSTI 2019, Tallinn
Hepatitis E is one of the most common causes of acute hepatitis in the EU/EEA but currently not notifiable at EU level.
This presentation summarises ECDC's work on the topic and survey results on hepatitis E on 2005 to 2015 data.
Any questions? Contact press@ecdc.europa.eu
This presentation summarises the main data from the ECDC Annual epidemiological reports 2017 on chlamydia, gonorrhoea, lymphogranuloma venereum, (congenital) syphilis
Providing an overview on data, trends and summary of findings on the hepatitis B and C surveillance data from EU/EEA countries for the year 2017:
Find ECDC's Annual Epidemiological reports online: http://bit.ly/ECDCAER
HIV transmission remains a major public health concern and affects more than 2 million people in the WHO European Region.
These ECDC slides summarise findings from the report which is available via http://bit.ly/WAD_18
Data and trends from the ECDC Annual Epidemiological reports for 2016 on:
Chlamydia (http://bit.ly/AERch16)
Lymphogranuloma venereum (http://bit.ly/AERLGV16)
Gonorrhoea (http://bit.ly/AERsy16)
Syphilis (http://bit.ly/AERsy16)
Congenital syphilis (http://bit.ly/AERcs16)
See also: https://ecdc.europa.eu/en/annual-epidemiological-reports
Teymur Noori, ECDC
22nd International AIDS Conference, Amsterdam 2018
2018 European African HIV/AIDS & Hepatitis C Community Summit. "Our Voices Matter for a lasting solution!!"
Poster presentation at the AIDS 2018 conference in Amsterdam.
By: Adam Bourne1, Beatrice Alba1, Alex Garner2, Gianfranco Spiteri3, Anastasia Pharris3, Teymur Noori3
1. Australian Research Centre in Sex, Health & Society, La Trobe University, Melbourne, Australia; 2. Hornet Gay Social Network, California, USA; 3. European Centre for Disease Prevention and Control, ECDC, Sweden
Poster presentation at the AIDS 2018 conference in Amsterdam.
By: Marieke J. van der Werf and Csaba Ködmön, European Centre for Disease Prevention and Control, ECDC.
Summary of surveillance data for hepatitis B and hepatitis C across the European Union and European Economic area for 2016.
See also:
ECDC's Annual Epidemiological Report hepatitis B: http://bit.ly/AER16HBV
ECDC's Annual Epidemiological Report hepatitis C: http://bit.ly/AER16HCV
More from European Centre for Disease Prevention and Control (20)
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMSAkankshaAshtankar
MIP 201T & MPH 202T
ADVANCED BIOPHARMACEUTICS & PHARMACOKINETICS : UNIT 5
APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS By - AKANKSHA ASHTANKAR
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Oleg Kshivets
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
Top 10 Best Ayurvedic Kidney Stone Syrups in India
Overview of the HIV continuum of care in Europe and Central Asia, 2018
1. #AIDS2018 | @AIDS_conference | www.aids2018.org
Overview of the HIV continuum of
care in Europe and Central Asia
Teymur Noori
European Centre for Disease Prevention and Control
Sweden
2. Overview of the HIV continuum of care in
Europe and Central Asia
Teymur Noori, ECDC
22nd International AIDS Conference, Amsterdam 2018
ECDC/EACS satellite: Getting to 90: Addressing inequalities in the HIV continuum of care in Europe and Central Asia
Monday 23 July 2018 – 12:30-14:30
3. Disclosure
Employed by the European Centre for Disease Prevention and Control
No potential conflict of interests
4. Outline
Show progress toward achieving the global 90-90-90
treatment targets in Europe and Central Asia
Highlight the inequalities along the continuum in our region
by focusing on the variation:
− between countries
− between sub-regions
− within sub-regions
5. >160 000 persons were diagnosed with HIV in the
WHO European Region in 2016
Source: ECDC/WHO (2017). HIV/AIDS Surveillance in Europe 2017– 2016 data
East
80%
≈ 128,000
cases
Centre
4%
≈ 5,800
cases
West
16%
≈ 26,000
cases
6. Data availability on the continuum of care
2014 (n=40); 2016 (n=44); 2018 (n=43)
Source: ECDC. Dublin Declaration monitoring 2018; validated unpublished data.
11
25
37
35
26
16
4
37
42
41
31
29
9
41
42 42
37
34
0
10
20
30
40
50
No data PLHIV Diagnosed On ART Viral suppression All stages
Nrofcountriesreportingdata
2014 2016 2018
Promoting
collaboration
between clinical,
public health and
community bodies
7. Fast Track Targets by 2020
73%
of all people living
with HIV
VIRALLY
SUPPRESSED
=
Target 1 Target 2 Target 3 Overall target
diagnosed with HIV
ON ART
living with HIV
DIAGNOSED
on ART
VIRALLY
SUPPRESSED
8. Fast Track Targets by 2020
73%
of all people living
with HIV
VIRALLY
SUPPRESSED
=
Target 1 Target 2 Target 3
diagnosed with HIV
ON ART
living with HIV
DIAGNOSED
on ART
VIRALLY
SUPPRESSED
Overall target
9. Progress toward achieving the 1st 90:
90% of all PLHIV who know their status (n=39)
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Global target 90%
Regional average 80%
Source: ECDC. Dublin Declaration monitoring 2018; validated unpublished data.
Latest available data reported, ranging from 2014-2017.
Target reached Above regional average Below regional average
10. Progress toward achieving the 1st 90:
Sub-regional variation: West, Centre, East
Source: ECDC. Dublin Declaration monitoring 2018; validated unpublished data.
11. Significant within sub-region variation in
achieving the 1st 90 (diagnoses)
74-93%
46-90%
48-94%
Source: ECDC. Dublin Declaration monitoring 2018; validated unpublished data.
12. Fast Track Targets by 2020
73%
of all people living
with HIV
VIRALLY
SUPPRESSED
=
Target 1 Target 2 Target 3
diagnosed with HIV
ON ART
living with HIV
DIAGNOSED
on ART
VIRALLY
SUPPRESSED
Overall target
13. Progress toward achieving the 2nd 90:
90% of those diagnosed on ART (n=40)
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Global target 90%
Regional average 64%
Source: ECDC. Dublin Declaration monitoring 2018; validated unpublished data.
Latest available data reported, ranging from 2014-2017.
Target reached Above regional average Below regional average
21. Availability of ART for undocumented migrants
2018
Source: ECDC. From Dublin to Rome: ten years of responding to HIV in Europe and Central Asia: Stockholm, ECDC; 2014
Source: ECDC. Dublin Declaration monitoring 2018; validated unpublished data.
22. Fast Track Targets by 2020
73%
of all people living
with HIV
VIRALLY
SUPPRESSED
=
Target 1 Target 2 Target 3
diagnosed with HIV
ON ART
living with HIV
DIAGNOSED
on ART
VIRALLY
SUPPRESSED
Overall target
23. Progress toward achieving the 3rd 90:
90% of those on ART virally suppressed (n=35)
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100% Global target 90%
Regional average 85%
Source: ECDC. Dublin Declaration monitoring 2018; validated unpublished data.
Latest available data reported, ranging from 2014-2017.
Target reached Above regional average Below regional average
24. Progress toward achieving the 3rd 90:
Significant sub-regional variation: West, Centre, East
Source: ECDC. Dublin Declaration monitoring 2018; validated unpublished data.
25. Significant within sub-region variation in
achieving the 3rd 90 (viral suppression)
32-98%
14-99%
42-86%
Source: ECDC. Dublin Declaration monitoring 2018; validated unpublished data.
26. Fast Track Targets by 2020
73%
of all people living
with HIV
VIRALLY
SUPPRESSED
=
Target 1 Target 2 Target 3
diagnosed with HIV
ON ART
living with HIV
DIAGNOSED
on ART
VIRALLY
SUPPRESSED
Overall target
27. Progress toward achieving the overall target:
73% of all PLHIV virally suppressed (n=34)
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Regional average 43%
Global target 73%
Source: ECDC. Dublin Declaration monitoring 2018; validated unpublished data.
Latest available data reported, ranging from 2014-2017.
Target reached Above regional average Below regional average
28. Progress toward achieving the overall 90-90-90 target:
Significant sub-regional variation: West, Centre, East
Source: ECDC. Dublin Declaration monitoring 2018; validated unpublished data.
29. 20-87%
6-54%
22-36%
Significant within sub-region variation in achieving the
overall 90-90-90 target (73% viral suppression of all PLHIV)
Source: ECDC. Dublin Declaration monitoring 2018; validated unpublished data.
30. Is community viral load/undiagnosed fraction impacting
new HIV diagnoses in Europe and Central Asia?
0
10
20
30
40
50
60
2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Newdiagnosesper100000population
West
Centre
East
Source: ECDC/WHO (2017). HIV/AIDS Surveillance in Europe 2017– 2016 data
Source: ECDC. Dublin Declaration monitoring 2018; validated unpublished data on the continuum of care.
• 26% viral suppression
• 24% undiagnosed
• 95% increase in diagnoses
• 72% viral suppression
• 14% undiagnosed
• 19% decline in diagnoses
• 45% viral suppression
• 17% undiagnosed
• 147% increase in diagnoses
Estimates at a single
point in time
Trend data
35. Conclusions
Significant variation along all steps of the continuum of care
between and within the sub-regions of Europe and Central Asia
ONTREATMENT
VIRAL
SUPPRESSION
DIAGNOSED
PLHIV
TESTING
LINKAGE TO
CARE
RETENTION &
ADHERENCE
SUPPORT
72%
OF ALL PLHIV
IN WEST ARE
VIRALLY
SUPPRESSED
QUALITY OF
LIFE
45%
OF ALL PLHIV
IN CENTRE
ARE VIRALLY
SUPPRESSED
26%
OF ALL PLHIV
IN EAST ARE
VIRALLY
SUPPRESSED
PREVENTION
While the Western part of the region is closing in on reaching the
90-90-90 targets, the Central and Eastern parts are lagging behind
Priorities:
Source: ECDC. Dublin Declaration monitoring 2018; validated unpublished data.
36. Acknowledgements
Dublin Declaration advisory group
Kristi Ruutel (Estonia), Daniela Rojas Castro (France), Gesa Kupfer (Germany), Caroline Hurley (Ireland), Silke David (Netherlands), Arild Johan Myrberg
(Norway), Isabel Aldir, Daniel Simoes (Portugal), Irene Klavs (Slovenia), Gabrella Hok (Sweden), Valerie Delpech, Alison Brown, Cary James, Brian Rice (United
Kingdom), Olga Varetska (Ukraine), Jean-Luc Sion (European Commission), Dagmar Hedrich (EMCDDA), Taavi Erkkola, Kim Marsh (UNAIDS), Annemarie
Stengaard (WHO Regional Office for Europe), Jordi Casabona (INEGRATE), Axel J. Schmidt (ESTICOM).
Dublin Declaration focal points in Europe and Central Asia
Roland Bani (Albania), Jennifer Fernández Garcia (Andorra), Samvel Grigoryan, Arshak Papoyan (Armenia), Irene Rueckerl, Bernhard Benka, Robert Zangerle
(Austria), Esmira Almammadova, Natig Zulfugarov (Azerbaijan), Inna Karabakh (Belarus), Andre Sasse, Dominique Van Beckhoven (Belgium), Dušan Kojić,
Indira Hodžić (Bosnia and Herzegovina), Tonka Varleva (Bulgaria), Jasmina Pavlic (Croatia), Ioannis Demetriades (Cyprus), Veronika Šikolová, Hana Janatova
(Czech Republic), Jan Fouchard (Denmark), Kristi Rüütel, Liilia Lõhmus, Anna-Liisa Pääsukene (Estonia), Henrikki Brummer-Korvenkontio (Finland), Bernard
Faliu (France), Maia Tsereteli, Otar Chokoshvili, Ana Aslanikashvili (Georgia), Gesa Kupfer, Ulrich Marcus, (Germany), Dimitra Paraskeva, Vasilios Raftopoulos,
Stavros Patrinos, (Greece), Maria Dudas, Katalin Szalay (Hungary), Guðrún Sigmundsdóttir, Þórólfur Guðnason (Iceland), Caroline Hurley, Fiona Lyons, Derval
Igoe, Helen Deely, (Ireland), Daniel Chemtob, Yana Roshal (Israel), Anna Caraglia, Francesco Maraglino, Barbara Suligoi, Lella Cosmaro, (Italy), Alla Yelizarieva,
Aliya Bokazhanova (Kazakhstan), Laura Shehu, Pashk Buzhala (Kosovo*), Aikul Ismailova, Nazgul Asylalieva (Kyrgyzstan), Šarlote Konova (Latvia), Andrea
Leibold. Marina Jamnicki Abegg (Liechtenstein), Irma Caplinskiene (Lithuania), Patrick Hoffman, Pierre Weicherding (Luxembourg), Milena Stefanovic,
Vladimir Mikic (FYROM), Jackie Maistre Melillo (Malta), Iulian Oltu, Svetlana Popovici, Tatiana Cotelnic (Moldova), Alma Cicic, Aleksandra Marjanovic
(Montenegro), Silke David (Netherlands), Arild Johan Myrberg (Norway), Anna Marzec- Bogusławska, Iwona Wawer, Piotr Wysocki, Magdalena Rosinska
(Poland), Isabel Aldir, Teresa Melo (Portugal), Mariana Mardarescu, Adrian Streinu-Cercel (Romania), Danijela Simic, Sladjana Baros (Serbia), Jan Mikas, Peter
Truska, Helena Hudecová, (Slovakia), Irena Klavs, Janez Tomažič (Slovenia), Begona Rodriquez Ortiz de Salazar (Spain), Louise Mannheimer, Gabriella Hok,
(Sweden), Axel J. Schmidt, Sabine Basler (Switzerland), Zukhra Nurlaminova, Sayfuddin Karimov, Dilshod Sayburhonov (Tajikistan), Emel Özdemir Şahin
(Turkey), Valerie Delpech (United Kingdom), Igor Kuzin (Ukraine) and Zulfiya Abdurakhimova (Uzbekistan).
HIV Surveillance focal points in the EU/EEA
Daniela Schmid, Alexander Spina (Austria), Andre Sasse (Belgium), Tonka Varleva (Bulgaria), Tatjana Nemeth Blazic (Croatia); Maria Koliou (Cyprus), Marek
Maly (Czech Republic); Susan Cowan (Denmark), Kristi Ruutel (Estonia), Kirsi Liitsola (Finland), Florence Lot (France), Barbara Gunsenheimer-Bartmeyer
(Germany), Georgios Nikolopoulos and Dimitra Paraskeva (Greece), Maria Dudas (Hungary), Gudrun Sigmundsdottir and Haraldur Briem (Iceland), Kate
O’Donnell and Derval Igoe (Ireland), Barbara Suligoi (Italy), Šarlote Konova (Latvia), Saulius Čaplinskas and Irma Čaplinskienė (Lithuania), : Jean-Claude Schmit
(Luxembourg), Jackie Maistre Melillo and Tanya Melillo (Malta), Eline Op de Coul (Netherlands), Hans Blystad (Norway), Magdalena Rosinska (Poland),
Helena Cortes Martins (Portugal), Mariana Mardarescu (Romania), Peter Truska (Slovakia), Irena Klavs (Slovenia), Asuncion Diaz (Spain), Maria Axelsson
(Sweden), Valerie Delpech (United Kingdom).
EuroCoord/ECDC project collaborators
Daniela Schmid, Alexander Spina, Robert Zangerle (Austria), Andre Sasse, Dominique Van Beckhoven (Belgium), Susan Cowan, Niels Obel (Denmark),
Florence Lot, Francoise Cazein, Dominique Costagliola, Virginie Supervie (France), Barbara Gunsenheimer-Bartmeyer (Germany), Georgios Nikolopoulos,
Giota Touloumi (Greece), Barbara Suligoi, Antonella d’ Arminio Monforte, Enrico Girardi (Italy), Eline Op de Coul, Peter Reiss, Ard van Sighem (Netherlands),
Mercedes Diez, Asuncion Diaz, Julia Del Amo (Spain), Maria Axelsson, Anders Sӧnnerborg (Sweden), Valerie Delpech, Sara Croxford, Caroline Sabin (United
Kingdom)